scholarly article | Q13442814 |
meta-analysis | Q815382 |
P2093 | author name string | Haruhiko Nakamura | |
Norihito Kawasaki | |||
Masahiko Taguchi | |||
Kazuyuki Kabasawa | |||
P2860 | cites work | Bias in meta-analysis detected by a simple, graphical test | Q24685585 |
EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy | Q27824812 | ||
Operating characteristics of a rank correlation test for publication bias | Q27860653 | ||
Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene | Q27860693 | ||
Meta-analysis in clinical trials | Q27860779 | ||
Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage | Q28272540 | ||
A biological staging model for operable non-small cell lung cancer | Q28367155 | ||
Aneuploidy and prognosis of non-small-cell lung cancer: a meta-analysis of published data | Q30655546 | ||
HER-2, EGFR, COX-2 expression status correlated to microvessel density and survival in resected non-small cell lung cancer | Q33201126 | ||
Trastuzumab in the treatment of advanced non-small-cell lung cancer: is there a role? Focus on Eastern Cooperative Oncology Group study 2598. | Q33359693 | ||
C-erbB-2 expression and codon 12 K-ras mutations both predict shortened survival for patients with pulmonary adenocarcinomas. | Q34124421 | ||
Overview of treatment results with trastuzumab (Herceptin) in metastatic breast cancer | Q34483005 | ||
Beta blockade during and after myocardial infarction: an overview of the randomized trials | Q34557544 | ||
Gefitinib (Iressa) trials in non-small cell lung cancer | Q35179411 | ||
The role of HER-2/neu expression on the survival of patients with lung cancer: a systematic review of the literature | Q35216052 | ||
Immunohistochemical typing of non-small cell lung cancer on cryostat sections: correlation with clinical parameters and prognosis | Q35587101 | ||
Lack of prognostic significance of epidermal growth factor receptor and the oncoprotein p185HER-2 in patients with systemically untreated non-small-cell lung cancer: an immunohistochemical study on cryosections | Q36135626 | ||
Influence of angiogenetic factors and matrix metalloproteinases upon tumour progression in non-small-cell lung cancer | Q36623274 | ||
Multiple molecular marker testing (p53, C-Ki-ras, c-erbB-2) improves estimation of prognosis in potentially curative resected non-small cell lung cancer | Q36642239 | ||
Serum EGF-receptor and HER-2 extracellular domains and prognosis of non-small-cell lung cancer | Q36695530 | ||
Angiogenesis and molecular biologic substaging in patients with stage I non-small cell lung cancer | Q36799412 | ||
Paclitaxel resistance in non-small-cell lung cancer associated with beta-tubulin gene mutations | Q38318461 | ||
Sialomucin expression is associated with erbB-2 oncoprotein overexpression, early recurrence, and cancer death in non-small-cell lung cancer | Q38475099 | ||
Prognostic value of the quantified expression of p185 in non-small cell lung cancer. | Q40762548 | ||
HER-2/neu oncogene protein and prognosis in breast cancer | Q41927421 | ||
Prognostic significance of HER-2/neu overexpression in stage I adenocarcinoma of lung | Q43531194 | ||
Correlation between encoded protein overexpression and copy number of the HER2 gene with survival in non-small cell lung cancer | Q44231768 | ||
Phosphorylation, But Not Overexpression, of Epidermal Growth Factor Receptor Is Associated With Poor Prognosis of Non-Small Cell Lung Cancer Patients | Q44399179 | ||
Synchronous overexpression of epidermal growth factor receptor and HER2-neu protein is a predictor of poor outcome in patients with stage I non-small cell lung cancer | Q47252774 | ||
Effect of HER2/neu expression on survival in non-small-cell lung cancer | Q47289478 | ||
Measurement of chemoresistance markers in patients with stage III non-small cell lung cancer: a novel approach for patient selection | Q47782716 | ||
Molecular pathologic substaging in 244 stage I non-small-cell lung cancer patients: clinical implications | Q50876150 | ||
Language bias in randomised controlled trials published in English and German. | Q53358085 | ||
Overexpression of the c-erbB-2/neu-encoded p185 protein in primary lung cancer | Q53494420 | ||
Study of prognostic predictors for non-small cell lung cancer. | Q53759964 | ||
Potential role ofbcl-2 as a suppressor of tumour angiogenesis in non-small-cell lung cancer | Q58212345 | ||
N-Myc gene amplification is a major prognostic factor in localized neuroblastoma: results of the French NBL 90 study. Neuroblastoma Study Group of the Société Francaise d'Oncologie Pédiatrique | Q60035759 | ||
Publication Bias: A Problem in Interpreting Medical Data | Q63018176 | ||
Prognostic influence of the co-expression of epidermal growth factor receptor and c-erbB-2 protein in human lung adenocarcinoma | Q72784859 | ||
Clinicopathologic analysis of k-ras, p53, and ERBB-2 gene alterations in pulmonary adenocarcinoma | Q73063449 | ||
p53, c-erbB-2 and nm23 expression have no prognostic significance in primary pulmonary adenocarcinoma | Q73443407 | ||
Immunocytochemical markers in stage I lung cancer: relevance to prognosis | Q73585186 | ||
Molecular biologic substaging of stage I lung cancer according to gender and histology | Q73633029 | ||
Prognostic value of K-ras mutations, ras oncoprotein, and c-erb B-2 oncoprotein expression in adenocarcinoma of the lung | Q74427809 | ||
Do molecular markers predict survival in non-small-cell lung cancer? | Q74489957 | ||
Vascular endothelial growth factor and other biological predictors related to the postoperative survival rate on non-small cell lung cancer | Q74498678 | ||
The interactive effect of Ras, HER2, P53 and Bcl-2 expression in predicting the survival of non-small cell lung cancer patients | Q74522923 | ||
HER-2/neu overexpression in patients with radically resected nonsmall cell lung carcinoma. Impact on long-term survival | Q74599860 | ||
A biologic risk model for stage I lung cancer: immunohistochemical analysis of 408 patients with the use of ten molecular markers | Q74652194 | ||
Study of pretreatment serum levels of HER-2/neu oncoprotein as a prognostic and predictive factor in patients with advanced nonsmall cell lung carcinoma | Q77357239 | ||
Publishing negative data: beta-tubulin mutations in lung cancer | Q77374037 | ||
Prognostic value of immunohistochemical expressions of p53, HER-2/neu, and bcl-2 in stage I non-small-cell lung cancer | Q77585746 | ||
Analysis of neuroendocrine markers, HER2 and CEA before and after chemotherapy in patients with stage IIIA non-small cell lung cancer: a Cancer and Leukemia Group B study | Q77700543 | ||
P433 | issue | 9 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | meta-analysis | Q815382 |
lung carcinoma | Q18556110 | ||
overexpression | Q61643320 | ||
P304 | page(s) | 1865-1873 | |
P577 | publication date | 2005-05-01 | |
P1433 | published in | Cancer | Q326041 |
P1476 | title | Association of HER-2 overexpression with prognosis in nonsmall cell lung carcinoma: a metaanalysis | |
P478 | volume | 103 |